AbbVie Expands Board to 13 Members, Appoints Dr. John M. Carethers

Event Overview

On October 14, 2026, AbbVie Inc. filed a Current Report on Form 8-K under Item 5.02 reporting the expansion of its Board of Directors and the appointment of a new director.

Key Highlights

• Board Expansion: AbbVie expanded the size of its Board of Directors from 12 to 13 members.
• New Director: Dr. John M. Carethers was appointed as a Class II director.
• Background: Dr. Carethers serves as the Vice Chancellor for Health Sciences at the University of California San Diego and previously served as a director of Avantor, Inc.
• Committee Appointments: Appointed to serve on AbbVie's Public Policy and Sustainability Committee.
• Director Independence: The Board affirmatively determined that Dr. Carethers qualifies as an "independent director" under Section 303A.02 of the NYSE Listed Company Manual and AbbVie's Director Independence Guidelines.
• Compensation: Dr. Carethers will receive standard non-employee director compensation as disclosed in Exhibit 10.5 to AbbVie's Form 10-Q for the quarter ended March 31, 2025.

Market and Governance Impact

This filing represents standard board succession and governance strengthening, adding clinical and academic health sciences expertise to AbbVie's board oversight. It carries Low trading significance, as it does not involve share transactions or unexpected executive turnover.